期刊
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
卷 23, 期 -, 页码 S15-S22出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1521-690X(09)70004-1
关键词
Cushing's syndrome; Cushing's disease; adrenocorticotrophic hormone (ACTH); pituitary
资金
- NEON
- Novartis Pharma
- National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish
Cushing's disease results from prolonged overexposure of tissues to endogenous glucocorticoids, secondary to adrenocorticotrophin excess from the pituitary. Common clinical signs and symptoms include weight gain, hypertension, and osteoporosis. Effective treatment of Cushing's disease can normalize biochemical levels, reverse comorbidities, and improve overall survival and quality of life. Treatment options include pituitary or adrenal surgery, radiotherapy, and various medical therapies, but each has important limitations. Medical therapies that effectively target the pituitary tumour are urgently needed. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据